Jochen Wöhrle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jochen Wöhrle has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Wolfgang Rottbauer
Department of Internal Medicine II University of Ulm Ulm Germany
30 shared publicationsBirgid Gonska
Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany
29 shared publicationsJulia Seeger
22 shared publicationsChristoph Rodewald
Department of Internal Medicine II - Cardiology, University of Ulm, Ulm, Germany
16 shared publications- Wolfgang Rottbauer
Ulm University Heart Center
15 shared publications - Julia Seeger
Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
13 shared publications
Latest Publications
- Open Access
- 19 November 2018
- Published by MDPI AG in Biomolecules
- Vol. 8 (4) , 152
Atrial Fibrillation Predicts Long-Term Outcome after Transcatheter Edge-to-Edge Mitral Valve Repair by MitraClip Implantation
Background: Atrial fibrillation is common in patients with mitral regurgitation (MR) and has a negative impact on the clinical outcome of patients with valvular heart disease. We aimed to evaluate the impact of pre-procedural atrial fibrillation on the long-term clinical outcomes of patients with MR undergoing transcatheter mitral valve repair by MitraClip implantation. Methods: We analysed 355 consecutive patients with and without atrial fibrillation with symptomatic, severe MR and inoperability or high surgical risk undergoing MitraClip implantation in a three-year follow-up. Results: In patients with pre-procedural atrial fibrillation undergoing MitraClip implantation, we found advanced age, higher baseline NT-pro-BNP levels, increased left atrial diameter, and higher rate of severe tricuspid regurgitation, compared to patients with sinus rhythm. In the three-year follow-up after MitraClip implantation, mortality and major adverse cardiovascular and cerebral events (MACCE) occur significantly more often in patients with atrial fibrillation, compared to patients without atrial fibrillation. Multivariate regression analysis confirmed atrial fibrillation (hazard ratio 2.39, 95%-confidence interval 1.06–5.41, p = 0.036) as an independent predictor for three-year-mortality after MitraClip implantation. Conclusions: Atrial fibrillation is an independent predictor for long-term mortality after MitraClip implantation. We demonstrate the association of atrial fibrillation with mortality and MACCE in the long-term follow-up of patients undergoing MitraClip implantation.
- 19 November 2018
- Published by MDPI AG in Biomolecules
- Vol. 8 (4) , 152
Open AccessAtrial Fibrillation Predicts Long-Term Outcome after Transcatheter Edge-to-Edge Mitral Valve Repair by MitraClip Implantation
Background: Atrial fibrillation is common in patients with mitral regurgitation (MR) and has a negative impact on the clinical outcome of patients with valvular heart disease. We aimed to evaluate the impact of pre-procedural atrial fibrillation on the long-term clinical outcomes of patients with MR undergoing transcatheter mitral valve repair by MitraClip implantation. Methods: We analysed 355 consecutive patients with and without atrial fibrillation with symptomatic, severe MR and inoperability or high surgical risk undergoing MitraClip implantation in a three-year follow-up. Results: In patients with pre-procedural atrial fibrillation undergoing MitraClip implantation, we found advanced age, higher baseline NT-pro-BNP levels, increased left atrial diameter, and higher rate of severe tricuspid regurgitation, compared to patients with sinus rhythm. In the three-year follow-up after MitraClip implantation, mortality and major adverse cardiovascular and cerebral events (MACCE) occur significantly more often in patients with atrial fibrillation, compared to patients without atrial fibrillation. Multivariate regression analysis confirmed atrial fibrillation (hazard ratio 2.39, 95%-confidence interval 1.06–5.41, p = 0.036) as an independent predictor for three-year-mortality after MitraClip implantation. Conclusions: Atrial fibrillation is an independent predictor for long-term mortality after MitraClip implantation. We demonstrate the association of atrial fibrillation with mortality and MACCE in the long-term follow-up of patients undergoing MitraClip implantation.
- Open Access
- 15 November 2018
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 26 (12) , 620-627
Influence of permanent pacemaker implantation after transcatheter aortic valve implantation with new-generation devices
Permanent pacemaker implantation (PPMI) after transcatheter aortic valve implantation (TAVI) is the most common complication after the procedure. PPMI rates remain high with the new-generation TAVI devices despite improved outcomes concerning paravalvular aortic regurgitation and vascular access complications. However, the impact of PPMI on mortality and clinical outcome is still a matter of debate, and data with new-generation devices on this matter are scarce. Therefore, we sought to analyse the influence of PPMI in patients treated with the new-generation devices on one-year outcome.
- 15 November 2018
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 26 (12) , 620-627
Open AccessInfluence of permanent pacemaker implantation after transcatheter aortic valve implantation with new-generation devices
Permanent pacemaker implantation (PPMI) after transcatheter aortic valve implantation (TAVI) is the most common complication after the procedure. PPMI rates remain high with the new-generation TAVI devices despite improved outcomes concerning paravalvular aortic regurgitation and vascular access complications. However, the impact of PPMI on mortality and clinical outcome is still a matter of debate, and data with new-generation devices on this matter are scarce. Therefore, we sought to analyse the influence of PPMI in patients treated with the new-generation devices on one-year outcome.
- 8 October 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (3) , 538-544
Long‐term clinical outcome of persistent left bundle branch block after transfemoral aortic valve implantation
Objective: The impact of persistent left bundle‐branch block (pLBBB) on long‐term clinical outcome remains to be determined.Background: New‐onset of pLBBB occurs frequently after transfemoral aortic valve implantation (TAVI).Methods: Seven hundred and seven consecutive patients who underwent TAVI were analyzed for baseline and procedural characteristics and clinical outcome in an up to 2‐year follow‐up. Patients were divided into either a group with pLBBB until hospital discharge or a group without LBBB. We performed propensity‐score matching and analyzed baseline characteristics, procedural data and clinical outcome of both groups. Patients received balloon‐expandable valves in 56.4%, mechanically expandable valves in 37.5%, and self‐expandable valves in 6.3%.Results: A new‐onset, pLBBB was observed in 47.5% of patients after TAVI. The implantation of a mechanically expandable valve was associated with higher rate of pLBBB (54.2% vs. 20.8%, P < 0.001), whereas implantation of a balloon‐expandable valve was associated with lower incidence of pLBBB (39.8% vs. 73.1%, P < 0.001). Deeper ventricular implantation at left‐coronary side led to higher rates of pLBBB (7.5 ± 2.5 vs. 6.7 ± 2.6 mm, P < 0.001). The occurrence of pLBBB was associated with higher rates of permanent pacemaker implantation (40.9% vs. 15.9%, P < 0.001). By multivariate analysis, implantation of a mechanically expandable valve (Boston Scientific Lotus valve) was identified as independent predictor of occurrence of pLBBB (odds ratio 4.7, confidence interval 3.2–7.0, P < 0.001). In the 2‐year follow‐up, there were no significant differences between “pLBBB” and “no LBBB”—groups regarding mortality and rehospitalization due to heart failure.Conclusions: The occurrence of pLBBB is associated with the choice of valve type and implantation depth and requires significantly higher rates of permanent pacemaker implantations. Importantly, there are no differences in the 2‐year follow‐up regarding mortality and rehospitalization due to heart failure.
- 8 October 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (3) , 538-544
Long‐term clinical outcome of persistent left bundle branch block after transfemoral aortic valve implantation
Objective: The impact of persistent left bundle‐branch block (pLBBB) on long‐term clinical outcome remains to be determined.Background: New‐onset of pLBBB occurs frequently after transfemoral aortic valve implantation (TAVI).Methods: Seven hundred and seven consecutive patients who underwent TAVI were analyzed for baseline and procedural characteristics and clinical outcome in an up to 2‐year follow‐up. Patients were divided into either a group with pLBBB until hospital discharge or a group without LBBB. We performed propensity‐score matching and analyzed baseline characteristics, procedural data and clinical outcome of both groups. Patients received balloon‐expandable valves in 56.4%, mechanically expandable valves in 37.5%, and self‐expandable valves in 6.3%.Results: A new‐onset, pLBBB was observed in 47.5% of patients after TAVI. The implantation of a mechanically expandable valve was associated with higher rate of pLBBB (54.2% vs. 20.8%, P < 0.001), whereas implantation of a balloon‐expandable valve was associated with lower incidence of pLBBB (39.8% vs. 73.1%, P < 0.001). Deeper ventricular implantation at left‐coronary side led to higher rates of pLBBB (7.5 ± 2.5 vs. 6.7 ± 2.6 mm, P < 0.001). The occurrence of pLBBB was associated with higher rates of permanent pacemaker implantation (40.9% vs. 15.9%, P < 0.001). By multivariate analysis, implantation of a mechanically expandable valve (Boston Scientific Lotus valve) was identified as independent predictor of occurrence of pLBBB (odds ratio 4.7, confidence interval 3.2–7.0, P < 0.001). In the 2‐year follow‐up, there were no significant differences between “pLBBB” and “no LBBB”—groups regarding mortality and rehospitalization due to heart failure.Conclusions: The occurrence of pLBBB is associated with the choice of valve type and implantation depth and requires significantly higher rates of permanent pacemaker implantations. Importantly, there are no differences in the 2‐year follow‐up regarding mortality and rehospitalization due to heart failure.
- 1 September 2018
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 11 (17) , 1683-1693
Significant Differences in Debris Captured by the Sentinel Dual-Filter Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Among Different Valve Types
- 1 September 2018
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 11 (17) , 1683-1693
Significant Differences in Debris Captured by the Sentinel Dual-Filter Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Among Different Valve Types
- 2 August 2018
- Published by Springer Nature in Die Innere Medizin
- Vol. 59 (9) , 993-996
Perkutane Koronarintervention bei stabiler Angina pectoris
- 2 August 2018
- Published by Springer Nature in Die Innere Medizin
- Vol. 59 (9) , 993-996
Perkutane Koronarintervention bei stabiler Angina pectoris
- 1 August 2018
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 29 (5) , 389-396
Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy
BackgroundIn randomized clinical trials, the risk of thrombotic events with the absorb bioresorbable vascular scaffold (BVS) was significantly higher than with metallic drug-eluting stents. We evaluated predictors of scaffold thrombosis in the large-scale, multicenter German-Austrian ABSORB RegIstRy.Methods and results3178 patients with treatment of 4252 lesions using 5020 scaffolds were included. Follow-up rate at 6 months was 97.4%. Forty-five (1.42%) patients experienced definite/probable scaffold thrombosis during follow-up. Multiple regression analysis showed implantation of absorb BVS in bifurcation lesions [odds ratio (OR): 4.43; 95% confidence interval (CI): 1.69-11.59; P=0.0024] or treatment in the years 2013/2014 (OR: 1.88; 95% CI: 1.02-3.47; P=0.04) to be significant predictors of scaffold thrombosis. Excluding bifurcation lesions, the incidence of definite/probable scaffold thrombosis decreased from 1.8% (95% CI: 1.17-2.64%) in 2013/2014 to 0.89% (95% CI: 0.5-1.46%) in 2015/2016. In the latter period, absorb BVS were implanted more often in younger patients with less complex de novo lesions, and debulking devices and postdilatation were used more frequently. Between the two treatment periods, there was a significant reduction in myocardial infarction (2.73-1.24%, P<0.01; OR: 0.45; 95% CI: 0.26-0.77), definite/probable scaffold thrombosis (1.79-0.88%, P<0.05; OR: 0.49; 95% CI: 0.26-0.93), and target lesion failure and revascularization during follow-up.ConclusionImproved procedural technique and more strict patient selection may explain a significant decrease in the absorb BVS thrombosis rates during the recruitment period of the large-scale German-Austrian ABSORB RegIstRy. In addition, treatment of bifurcation lesions was identified as an independent predictor of definite/probable scaffold thrombosis.
- 1 August 2018
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 29 (5) , 389-396
Predictors of early scaffold thrombosis: results from the multicenter prospective German-Austrian ABSORB RegIstRy
BackgroundIn randomized clinical trials, the risk of thrombotic events with the absorb bioresorbable vascular scaffold (BVS) was significantly higher than with metallic drug-eluting stents. We evaluated predictors of scaffold thrombosis in the large-scale, multicenter German-Austrian ABSORB RegIstRy.Methods and results3178 patients with treatment of 4252 lesions using 5020 scaffolds were included. Follow-up rate at 6 months was 97.4%. Forty-five (1.42%) patients experienced definite/probable scaffold thrombosis during follow-up. Multiple regression analysis showed implantation of absorb BVS in bifurcation lesions [odds ratio (OR): 4.43; 95% confidence interval (CI): 1.69-11.59; P=0.0024] or treatment in the years 2013/2014 (OR: 1.88; 95% CI: 1.02-3.47; P=0.04) to be significant predictors of scaffold thrombosis. Excluding bifurcation lesions, the incidence of definite/probable scaffold thrombosis decreased from 1.8% (95% CI: 1.17-2.64%) in 2013/2014 to 0.89% (95% CI: 0.5-1.46%) in 2015/2016. In the latter period, absorb BVS were implanted more often in younger patients with less complex de novo lesions, and debulking devices and postdilatation were used more frequently. Between the two treatment periods, there was a significant reduction in myocardial infarction (2.73-1.24%, P<0.01; OR: 0.45; 95% CI: 0.26-0.77), definite/probable scaffold thrombosis (1.79-0.88%, P<0.05; OR: 0.49; 95% CI: 0.26-0.93), and target lesion failure and revascularization during follow-up.ConclusionImproved procedural technique and more strict patient selection may explain a significant decrease in the absorb BVS thrombosis rates during the recruitment period of the large-scale German-Austrian ABSORB RegIstRy. In addition, treatment of bifurcation lesions was identified as an independent predictor of definite/probable scaffold thrombosis.
- 1 August 2018
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 111 (8-9) , 470-479
Transfemoral aortic valve implantation is more successful with the Edwards Sapien 3 compared with the Edwards XT for the treatment of symptomatic severe aortic stenosis
- 1 August 2018
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 111 (8-9) , 470-479
Transfemoral aortic valve implantation is more successful with the Edwards Sapien 3 compared with the Edwards XT for the treatment of symptomatic severe aortic stenosis
- 1 June 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 71 (6) , 598
Author's reply
- 16 February 2018
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 107 (6) , 507-516
Patient-specific registration of 3D CT angiography (CTA) with X-ray fluoroscopy for image fusion during transcatheter aortic valve implantation (TAVI) increases performance of the procedure
The aim of this study was to adapt patient-specifically a co-registration procedure for image fusion (IF) of a pre-interventional CT dataset with real-time X-ray (XR) fluoroscopy during transfemoral transcatheter aortic valve implantation (TAVI), enabling improved performance of the procedure.
- 16 February 2018
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 107 (6) , 507-516
Patient-specific registration of 3D CT angiography (CTA) with X-ray fluoroscopy for image fusion during transcatheter aortic valve implantation (TAVI) increases performance of the procedure
The aim of this study was to adapt patient-specifically a co-registration procedure for image fusion (IF) of a pre-interventional CT dataset with real-time X-ray (XR) fluoroscopy during transfemoral transcatheter aortic valve implantation (TAVI), enabling improved performance of the procedure.